Veronica H Flood

List of Publications by Year
in descending order

69 papers	1,635 citations	361413 20 h-index	302126 39 g-index
70 all docs	70 docs citations	70 times ranked	1011 citing authors

#	Article	IF	Citations
1	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Advances, 2021, 5, 280-300.	5.2	246
2	ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Advances, 2021, 5, 301-325.	5.2	152
3	Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor. Blood, 2010, 116, 280-286.	1.4	148
4	Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood, 2011, 117, e67-e74.	1.4	98
5	Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States. Blood, 2016, 127, 2481-2488.	1.4	96
6	VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population. Blood, 2012, 119, 2135-2140.	1.4	94
7	Crucial role for the VWF A1 domain in binding to type IV collagen. Blood, 2015, 125, 2297-2304.	1.4	88
8	Advances in the diagnosis and treatment of Von Willebrand disease. Blood, 2017, 130, 2386-2391.	1.4	64
9	Collagen Binding Provides a Sensitive Screen for Variant von Willebrand Disease. Clinical Chemistry, 2013, 59, 684-691.	3.2	52
10	Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage. Blood, 2012, 119, 4543-4553.	1.4	50
11	Treatment Modalities in Adolescents Who Present with Heavy Menstrual Bleeding. Journal of Pediatric and Adolescent Gynecology, 2018, 31, 451-458.	0.7	42
12	Perils, Problems, and Progress in Laboratory Diagnosis of von Willebrand Disease. Seminars in Thrombosis and Hemostasis, 2014, 40, 041-048.	2.7	32
13	An international survey to inform priorities for new guidelines on von Willebrand disease. Haemophilia, 2020, 26, 106-116.	2.1	32
14	Sustained engraftment post bone marrow transplant despite anti-platelet antibodies in Glanzmann thrombasthenia. Pediatric Blood and Cancer, 2005, 45, 971-975.	1.5	30
15	No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation. Blood, 2013, 121, 3742-3744.	1.4	28
16	The fibrinogen Aalpha R16C mutation results in fibrinolytic resistance. British Journal of Haematology, 2006, 134, 220-226.	2.5	26
17	<scp>v</scp>on Willebrand Disease in the United States: A Perspective from Wisconsin. Seminars in Thrombosis and Hemostasis, 2011, 37, 528-534.	2.7	26
18	Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Advances, 2019, 3, 2748-2750.	5.2	26

#	Article	IF	Citations
19	Hemorrhagic disease of the newborn despite vitamin K prophylaxis at birth. Pediatric Blood and Cancer, 2008, 50, 1075-1077.	1.5	23
20	Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy. Blood Advances, 2020, 4, 100-105.	5.2	20
21	New insights into genotype and phenotype of VWD. Hematology American Society of Hematology Education Program, 2014, 2014, 531-535.	2.5	19
22	Current issues in diagnosis and treatment of von Willebrand disease. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 34-41.	2.3	19
23	Advances in the diagnosis and treatment of Von Willebrand disease. Hematology American Society of Hematology Education Program, 2017, 2017, 379-384.	2.5	17
24	von Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and meta-analysis. Blood Advances, 2022, 6, 62-71.	5.2	17
25	Variable content of von Willebrand factor mutant monomer drives the phenotypic variability in a family with von Willebrand disease. Blood, 2015, 126, 262-269.	1.4	16
26	Gynecologic and obstetric management of women with von Willebrand disease: summary of 3 systematic reviews of the literature. Blood Advances, 2022, 6, 228-237.	5.2	15
27	Von Willebrand disease in the United States: perspective from the Zimmerman program. Annals of Blood, 2018, 3, 7-7.	0.4	14
28	Von Willebrand Disease. Hematology/Oncology Clinics of North America, 2021, 35, 1085-1101.	2.2	14
29	Von Willebrand factor is reversibly decreased during torpor in 13-lined ground squirrels. Journal of Comparative Physiology B: Biochemical, Systemic, and Environmental Physiology, 2016, 186, 131-139.	1.5	13
30	What have we learned from large population studies of von Willebrand disease?. Hematology American Society of Hematology Education Program, 2016, 2016, 670-677.	2.5	10
31	The role of genetics in the pathogenesis and diagnosis of type 1 Von Willebrand disease. Current Opinion in Hematology, 2019, 26, 331-335.	2.5	10
32	Laboratory variability in the diagnosis of type 2 VWD variants. Journal of Thrombosis and Haemostasis, 2021, 19, 131-138.	3.8	10
33	Fibrinogen Hershey IV: A novel dysfibrinogen with a Î³V411I mutation in the integrin Î±IIbÎ²3 binding site. Thrombosis and Haemostasis, 2008, 99, 1008-1012.	3.4	7
34	Surgical management of patients with von Willebrand disease: summary of 2 systematic reviews of the literature. Blood Advances, 2022, 6, 121-128.	5.2	7
35	Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability. British Journal of Haematology, 2007, 138, 117-124.	2.5	6
36	Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement. Pediatric Blood and Cancer, 2013, 60, 500-502.	1.5	6

#	Article	IF	Citations
37	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. Blood Advances, 2021, 5, 5023-5031.	5.2	6
38	CommonVWFsequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 390-398.	2.3	5
39	von Willebrand factor binding to myosin assists in coagulation. Blood Advances, 2020, 4, 174-180.	5.2	5
40	Fibronectin binding to von Willebrand factor occurs via the A1 domain. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12534.	2.3	5
41	von Willebrand disease: proposing definitions for future research. Blood Advances, 2021, 5, 565-569.	5.2	5
42	Outcomes of longâ€term von Willebrand factor prophylaxis use in von Willebrand disease: A systematic literature review. Haemophilia, 2022, 28, 373-387.	2.1	5
43	Longitudinal bleeding assessment in von willebrand disease utilising an interim bleeding score. Journal of Thrombosis and Haemostasis, 0, , .	3.8	5
44	New insights into genotype and phenotype of VWD. Hematology American Society of Hematology Education Program, 2014, 2014, 531-535.	2.5	4
45	Platelet-derived VWF in the stroke spotlight. Blood, 2015, 126, 1640-1641.	1.4	3
46	Laboratory assays of VWF activity and use of desmopressin trials in the diagnosis of VWD: a systematic review and meta-analysis. Blood Advances, 2022, 6, 3735-3745.	5.2	3
47	Response to â€œThe 2021 von Willebrand disease guidelines: Clarity and controversyâ€• Haemophilia, 2022, 28, 371-372.	2.1	3
48	Quantitative Analysis of VWF Multimer Structure: Discrimination Between VWD Subtypes. Blood, 2011, 118, 1215-1215.	1.4	2
49	The Management of Bleeding Risk in Von Willebrand Disease: Should Blood Group O Make a Difference?. Blood, 2014, 124, 2829-2829.	1.4	2
50	Identification of Copy Number Variants in Type 1 and Type 3 VWD by aCGH in the Zimmerman Program. Blood, 2016, 128, 872-872.	1.4	2
51	Fourteen Percent of Healthy African Americans Participating In the Zimmerman Program for the Molecular and Clinical Biology of VWD (ZPMCB VWD) Are Heterozygous for the VWF Gene Mutation H817Q Associated with Type 2N Von Willebrand Disease. Blood, 2010, 116, 239-239.	1.4	2
52	von Willebrand disease (VWD) and BATs: How do they connect and why should I care?. Haemophilia, 2022, 28, .	2.1	2
53	von Willebrand factor variant D1472H has no effect in mice with humanized VWF-platelet interactions. Blood Advances, 2020, 4, 4065-4068.	5.2	1
54	Critical Importance Of VWF Propeptide (VWFpp) In The Diagnosis Of Type 1 Von Willebrand Disease (VWD). Blood, 2013, 122, 331-331.	1.4	1

#	Article	IF	Citations
55	Evaluation of a Standardized Approach to the Diagnosis of Mild Platelet Function Defects: Recommendation for a Targeted Approach to the Diagnosis of Mild Platelet Function Defects and Identification of a Subset of Children with a "Developmental" Form. Blood, 2015, 126, 1052-1052.	1.4	1
56	Women leaders in hematology: Inspirations & insights. American Journal of Hematology, 2016, 91, S6-S34.	4.1	0
57	Screening for von Willebrand disease does not impact posttonsillectomy bleeding in a lowâ€risk population. Pediatric Blood and Cancer, 2021, 68, e29371.	1.5	0
58	The Paradoxical Hemorrhagic and Thrombotic Nature of the Fibrinogen AÎ± R16C Mutation.. Blood, 2004, 104, 1047-1047.	1.4	0
59	Effects of Impaired Fibrinopeptide A Cleavage on Fibrin Clot Structure: Studies with an AÎ± R16C Dysfibrinogen.. Blood, 2006, 108, 1617-1617.	1.4	0
60	A Novel VWF A3 Domain Mutation with Absent Binding to Type I and Type III Collagen.. Blood, 2009, 114, 541-541.	1.4	0
61	Low VWF:RCo In Subjects with VWF Polymorphisms D1472H and P1467S Due to Decreased Binding of Ristocetin to the VWF A1 Domain. Blood, 2010, 116, 2208-2208.	1.4	0
62	VWF Binding to Types I, III or VI Collagen In the ZPMCB-VWD with Identification of Subjects with Selective Reduced Plasma VWF:CB. Blood, 2010, 116, 235-235.	1.4	0
63	Von Willebrand Factor Collagen Binding Provides a Sensitive Screen for Identification of Type 2A and 2B Von Willebrand Disease. Blood, 2011, 118, 379-379.	1.4	0
64	Developmental Hemostasis. , 2012, , 3101-3113.		0
65	Phenotypic Variability in Carriers of Von Willebrand Factor Truncating Sequence Variants in the Zimmerman Program. Blood, 2014, 124, 2833-2833.	1.4	0
66	Bleeding Phenotype Observed in Murine Defect of VWF-Collagen 4 Interactions. Blood, 2015, 126, 211-211.	1.4	0
67	Prevalence of Low VWF, VWD, and Isolated Collagen Binding Defects in Subjects Undergoing Evaluation for VWD. Blood, 2015, 126, 1090-1090.	1.4	0
68	Von Willebrand Factor (VWF) Propeptide and Factor VIII (FVIII) Levels Identify the Contribution of Decreased Synthesis and/or Increased Clearance Mechanisms in the Pathogenesis of Type 1 Von Willebrand Disease (VWD) in the Zimmerman Program. Blood, 2016, 128, 874-874.	1.4	0
69	Variability in Bleeding Phenotype in Type 3 VWD Families. Blood, 2018, 132, 2466-2466.	1.4	0